DEFEROXAMINE MESYLATE
DEFEROXAMINE MESYLATE is indicated for the treatment of Iron Intoxication; Iron Overload; Chronic Anemia.
How DEFEROXAMINE MESYLATE Works
Deferoxamine mesylate chelates iron by forming a stable complex (ferrioxamine) that prevents the metal from engaging in further chemical reactions. It selectively chelates iron from ferritin and hemosiderin; however, it does not readily chelate iron from transferrin, nor does it interact with iron found in hemoglobin or cytochromes. The medication does not significantly increase the excretion of electrolytes or other trace metals. Stoichiometrically, 100 mg of deferoxamine mesylate is capable of binding approximately 8.5 mg of ferric iron.
Details
- Status
- Prescription
- First Approved
- 2004-03-17
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
DEFEROXAMINE MESYLATE Approval History
What DEFEROXAMINE MESYLATE Treats
3 indicationsDEFEROXAMINE MESYLATE is approved for 3 conditions since its original approval in 2004. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Iron Intoxication
- Iron Overload
- Chronic Anemia
DEFEROXAMINE MESYLATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06763055 INTERACT5 | ACT-GLOBAL_ICH_01 | Ph 3 | recruiting | The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL |
| NCT02175225 results posted | 2012P000005 U01NS074425 | Ph 2 | completed | Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial |
| NCT00598572 DFO In ICH | 2007P000288 1R01NS057127-01A1 | Ph 1 | completed | Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DEFEROXAMINE MESYLATE FDA Label Details
Indications & Usage
DEFEROXAMINE MESYLATE is indicated for the treatment of Iron Intoxication; Iron Overload; Chronic Anemia.
Looking for the branded version?
DESFERAL
Full clinical data, patents, trials, and competitive landscape for deferoxamine mesylate.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.